IL18 and neoplasm: Although simultaneous VP3, interleukin-24 [17], interleukin-18 [18], upregulations and survivin downregulation [19] seemed to show greater anti-tumor activity than VP3 alone, the combined effect of VP3 and shRNA on CD147 affecting tumor growth and progression is yet to be investigated.